SCHEMBL4429207

SCHEMBL4429207

Cn1c(=O)c(-c2ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c2)cc2cnc(N)nc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 6/20 0.55
MAPK14 Q16539 11/20 0.51
MAPK11 Q15759 6/20 0.51
SRC P12931 4/20 0.51
BRAF P15056 4/20 0.51
DDR2 Q16832 3/20 0.51
AXL P30530 2/20 0.51
EPHB4 P54760 2/20 0.51
PTK2 Q05397 2/20 0.51
PTK2B Q14289 2/20 0.51
MAPK9 P45984 2/20 0.51
ABL2 P42684 2/20 0.51
MAPK8 P45983 2/20 0.51
PLK4 O00444 1/20 0.51
ACOX3 O15254 1/20 0.51
MAP3K7 O43318 1/20 0.51
DYRK3 O43781 1/20 0.51
JAK2 O60674 1/20 0.51
ERN1 O75460 1/20 0.51
RPS6KA4 O75676 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5060539 0.92 ABL1 (0.55) ABL1MAPK14MAPK11SRCBRAF
SCHEMBL5061595 0.91 MAPK14 (0.46) ABL1MAPK14MAPK11SRCBRAF
SCHEMBL5065364 0.89 MAPK14 (0.53) MAPK14MAPK11SRCBRAFDDR2
SCHEMBL4563409 0.89 MAPK14 (0.53) ABL1MAPK14MAPK11SRCBRAF
SCHEMBL5066988 0.87 MAPK14 (0.44) MAPK14MAPK11SRCBRAFDDR2
SCHEMBL5065442 0.85 MAPK14 (0.57) ABL1MAPK14MAPK11SRCBRAF
SCHEMBL4423931 0.85 MAPK14 (0.43) ABL1MAPK14MAPK11SRCBRAF
SCHEMBL5065431 0.85 BRAF (0.46) ABL1MAPK14MAPK11SRCBRAF
SCHEMBL5067085 0.84 MAPK14 (0.46) MAPK14MAPK11SRCBRAFDDR2
SCHEMBL5062510 0.83 KCNJ6 (0.49) MAPK14MAPK11SRCBRAFDDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 ABL1 936/4885MAPK14 240/4885MAPK11 194/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ABL1 936/4885MAPK14 240/4885MAPK11 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.